Reflector

Uncertainty swirls on just how effective policy competition between the EU and UK on these much-needed products will be.

Report on lessons from crisis includes—and ignites—some criticism.

Some new EU plans "fly in the face" of innovation, critics contend.

Advancing the concept of "health competencies" remains elusive.

More opinions enter the mix as EU launches legislation review.

US pharma industry handcuffed by restrictions, group argues.

Region’s diversity plays against efforts to curtail counterfeit drugs.

Is agenda blurring the line between alliances and assimilation?

Member states air concerns over excess supplies of COVID vaccines.

No shortage of views being expressed on drug shortages.

Making sense of surprise rejection of draft proposals.

Patient safety and data protection concerns highlight hesitancy.

And, in equal measure, patients and doctors—as EU mulls new rules.

Proposed SoHO reform elicits wide support, but risks acknowledged.

Legislative-reform alliance makes for strange bedfellows.

Group’s ideas to change EU pricing rules draw captive audience.

The risky business of outmaneuvering Europe’s drug pricing authorities.

Fresh round of discussions around health technology assessment.

Efforts for a standardized approach coming to a head in Europe.

European Commission looks to relieve issues without legislation.

Looks to address disconnect between registration and reimbursement.

Lack of IP management plagues recent regulatory discussions.

Committee struggles to find a common treatment approach.

Treatment availability for rare disease patients under fire in Europe.

Report claims an imbalance in influence of tech-transfer decisions.

Summits, proposals outline advice on response to future pandemics.

Pandemic triggers urgency around supply chain initiatives.

The progress and stumbling blocks in building a formal EU system.

Draft plan looks beyond the immediate European health challenges.

Latest proposal explores boosting the powers of the EMA.